EP2385944A2 - Fluorhaltige verbindungen und anwendungsverfahren dafür - Google Patents
Fluorhaltige verbindungen und anwendungsverfahren dafürInfo
- Publication number
- EP2385944A2 EP2385944A2 EP10729595A EP10729595A EP2385944A2 EP 2385944 A2 EP2385944 A2 EP 2385944A2 EP 10729595 A EP10729595 A EP 10729595A EP 10729595 A EP10729595 A EP 10729595A EP 2385944 A2 EP2385944 A2 EP 2385944A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluorinated
- substituted
- fluorine
- invention features
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title abstract description 311
- 150000001875 compounds Chemical class 0.000 title abstract description 102
- 229910052731 fluorine Inorganic materials 0.000 title description 195
- 239000011737 fluorine Substances 0.000 title description 194
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 title description 13
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 14
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical class C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 12
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical class NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 12
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical class N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 11
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical class O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 11
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical class COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 11
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical class C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 claims description 11
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 11
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical class C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 11
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical class C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 claims description 11
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical class N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims description 11
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical class O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 11
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical class C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 11
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical class C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 11
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical class C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 11
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical class C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 11
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical class C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 claims description 11
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical class C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 11
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical class C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 11
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical class C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 11
- 150000004926 Imatinib derivatives Chemical class 0.000 claims description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 9
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical class C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 9
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical class N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 6
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical class C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 6
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical class C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 6
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical class C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 6
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical class C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 6
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical class CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical class C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 6
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 6
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 6
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical class O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 6
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 6
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical class OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 6
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical class C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 6
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical class CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims description 6
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical class C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 6
- 150000004923 Erlotinib derivatives Chemical class 0.000 claims description 6
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical class C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 6
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical class O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical class CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 6
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical class CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 claims description 6
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical class C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 6
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 claims description 6
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical class C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 6
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical class C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 6
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical class NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical class N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical class C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims description 6
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical class C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 6
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical class C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 6
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical class CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 6
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical class N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 6
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical class C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 6
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical class C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical class C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 6
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical class CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 6
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical class C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 6
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical class C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 6
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical class N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 6
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical class O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 6
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical class OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 6
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 6
- 150000001557 benzodiazepines Chemical class 0.000 claims description 6
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical class CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 claims description 6
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical class C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims description 6
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical class C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 6
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical class CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 6
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical class C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 6
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 6
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical class NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 6
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical class O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical class C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 6
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical class C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 6
- 229960003120 clonazepam Drugs 0.000 claims description 6
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical class C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims description 6
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical class C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 6
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical class C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical class N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical class CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 6
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical class C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 claims description 6
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical class N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical class O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 6
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical class C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 6
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical class C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 6
- 229960001848 lamotrigine Drugs 0.000 claims description 6
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical class C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 6
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical class C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims description 6
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical class C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 6
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical class C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 6
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical class O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 6
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical class C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical class C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 6
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical class C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 6
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical class C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 6
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical class C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 6
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical class C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 claims description 6
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical class C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 6
- KTOYYUONFQWSMW-UHFFFAOYSA-N pipotiazine palmitate Chemical class C1CC(CCOC(=O)CCCCCCCCCCCCCCC)CCN1CCCN1C2=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C21 KTOYYUONFQWSMW-UHFFFAOYSA-N 0.000 claims description 6
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical class C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 6
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical class CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 6
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical class C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 6
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical class C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 6
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical class C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 6
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical class ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 6
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical class C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 6
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical class C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 claims description 6
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical class ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 6
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical class C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 6
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical class C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 6
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical class C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 6
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical class C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims description 6
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical class C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 6
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical class CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims description 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical class C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 6
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical class N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 6
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical class C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 6
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical class CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 6
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical class C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims description 6
- 229960000762 perphenazine Drugs 0.000 claims description 4
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical class C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003598 promazine Drugs 0.000 claims description 4
- 229960002324 trifluoperazine Drugs 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 229960000794 baclofen Drugs 0.000 claims description 3
- 229960002507 benperidol Drugs 0.000 claims description 3
- 229960001081 benzatropine Drugs 0.000 claims description 3
- 229940049706 benzodiazepine Drugs 0.000 claims description 3
- 229960001058 bupropion Drugs 0.000 claims description 3
- 229960002495 buspirone Drugs 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- 229960001653 citalopram Drugs 0.000 claims description 3
- 229960001403 clobazam Drugs 0.000 claims description 3
- 229960004170 clozapine Drugs 0.000 claims description 3
- 229960003529 diazepam Drugs 0.000 claims description 3
- 229960001253 domperidone Drugs 0.000 claims description 3
- 229960001393 dosulepin Drugs 0.000 claims description 3
- 229960005426 doxepin Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- 229960002464 fluoxetine Drugs 0.000 claims description 3
- 229960002690 fluphenazine Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960003299 ketamine Drugs 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229960002813 lofepramine Drugs 0.000 claims description 3
- 229960003019 loprazolam Drugs 0.000 claims description 3
- 229960004391 lorazepam Drugs 0.000 claims description 3
- 229960000423 loxapine Drugs 0.000 claims description 3
- 229940042053 methotrimeprazine Drugs 0.000 claims description 3
- 229960001344 methylphenidate Drugs 0.000 claims description 3
- 229960003955 mianserin Drugs 0.000 claims description 3
- 229960004644 moclobemide Drugs 0.000 claims description 3
- 229960001165 modafinil Drugs 0.000 claims description 3
- 229960001454 nitrazepam Drugs 0.000 claims description 3
- 229960002841 oxypertine Drugs 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 229960000964 phenelzine Drugs 0.000 claims description 3
- 229960002695 phenobarbital Drugs 0.000 claims description 3
- 229960002036 phenytoin Drugs 0.000 claims description 3
- 229960003634 pimozide Drugs 0.000 claims description 3
- 229960002393 primidone Drugs 0.000 claims description 3
- 229960003111 prochlorperazine Drugs 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- 229960003770 reboxetine Drugs 0.000 claims description 3
- 229960004181 riluzole Drugs 0.000 claims description 3
- 229960003855 solifenacin Drugs 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229960003188 temazepam Drugs 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 229960004380 tramadol Drugs 0.000 claims description 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 3
- 229960003741 tranylcypromine Drugs 0.000 claims description 3
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 3
- 229960003688 tropisetron Drugs 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- 229960001475 zolpidem Drugs 0.000 claims description 3
- 229960002911 zonisamide Drugs 0.000 claims description 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical class C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical class C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 description 727
- 125000003118 aryl group Chemical group 0.000 description 641
- 239000001257 hydrogen Substances 0.000 description 388
- 229910052739 hydrogen Inorganic materials 0.000 description 388
- 125000001072 heteroaryl group Chemical group 0.000 description 364
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 304
- 150000003839 salts Chemical class 0.000 description 300
- 238000004519 manufacturing process Methods 0.000 description 270
- 125000001931 aliphatic group Chemical group 0.000 description 128
- 150000002367 halogens Chemical group 0.000 description 125
- 125000003107 substituted aryl group Chemical group 0.000 description 107
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 100
- 125000004429 atom Chemical group 0.000 description 94
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 87
- 125000000623 heterocyclic group Chemical group 0.000 description 78
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 62
- 125000004122 cyclic group Chemical group 0.000 description 51
- -1 -CN radical Chemical class 0.000 description 50
- 229910052736 halogen Inorganic materials 0.000 description 46
- 239000003446 ligand Substances 0.000 description 40
- 125000002837 carbocyclic group Chemical group 0.000 description 35
- 125000006239 protecting group Chemical group 0.000 description 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 32
- 239000012025 fluorinating agent Substances 0.000 description 31
- 125000004093 cyano group Chemical group *C#N 0.000 description 30
- 150000002894 organic compounds Chemical class 0.000 description 29
- 229910052763 palladium Inorganic materials 0.000 description 27
- 125000002252 acyl group Chemical group 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
- 125000002015 acyclic group Chemical group 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 22
- 125000004076 pyridyl group Chemical group 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 125000005842 heteroatom Chemical group 0.000 description 18
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 239000008177 pharmaceutical agent Substances 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 12
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 150000003573 thiols Chemical group 0.000 description 11
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 10
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 10
- 239000004098 Tetracycline Substances 0.000 description 10
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical class CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 10
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 125000004663 dialkyl amino group Chemical group 0.000 description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 235000019364 tetracycline Nutrition 0.000 description 10
- 150000003522 tetracyclines Chemical class 0.000 description 10
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 9
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical class O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 9
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical class C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 9
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical class N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 9
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical class CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000002421 cell wall Anatomy 0.000 description 9
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical class C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 9
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical class C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 9
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical class [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical class C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 9
- 229930101283 tetracycline Natural products 0.000 description 9
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 9
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical class OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000005110 aryl thio group Chemical group 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 229940124587 cephalosporin Drugs 0.000 description 8
- 125000005368 heteroarylthio group Chemical group 0.000 description 8
- 229910052709 silver Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000001780 cephalosporins Chemical class 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical class CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical class CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical class CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical class O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 239000012363 selectfluor Substances 0.000 description 6
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical class COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 6
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical class C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical class C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 5
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical class CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 5
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 5
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical class C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical class CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical class C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical class COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 5
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical class CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 5
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical class C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 5
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical class C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical class C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 5
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical class C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 5
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 5
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical class [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 5
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical class C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 5
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 5
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical class IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical class OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical class CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 5
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical class C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 5
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical class N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 5
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical class IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 5
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical class CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 5
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical class OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical class COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 5
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical class C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 5
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical class C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical class C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical class C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 5
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical class CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 5
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical class CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 5
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical class CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 5
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical class C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical class CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 5
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical class C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 5
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical class C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 5
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical class CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 5
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical class CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 150000004097 candesartan derivatives Chemical class 0.000 description 5
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical class N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 5
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical class COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 5
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical class C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 5
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical class O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 5
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical class CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 5
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical class S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 5
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical class S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 5
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical class O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 5
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical class [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 5
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical class S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 5
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical class S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 5
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 5
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical class [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 5
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical class N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 5
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical class C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 5
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical class C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical class CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 5
- CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical class CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 description 5
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical class C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 5
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical class ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 5
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical class C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical class OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 5
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical class C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 5
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical class C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 5
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical class CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 5
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical class C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 5
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical class C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 5
- 150000002159 estradiols Chemical class 0.000 description 5
- 150000002167 estrones Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical class C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 5
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical class N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical class C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical class C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 5
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical class O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 5
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical class C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 125000004475 heteroaralkyl group Chemical group 0.000 description 5
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical class ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 5
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical class C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical class C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- 201000006747 infectious mononucleosis Diseases 0.000 description 5
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 5
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical class CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 5
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical class C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 5
- 150000004106 losartan derivatives Chemical class 0.000 description 5
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical class CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 5
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical class CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 5
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical class COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 5
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical class C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 5
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical class C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 5
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical class C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 5
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical class C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 5
- FUWFSXZKBMCSKF-ZASNTINBSA-N nicofuranose Chemical class C([C@]1(O)[C@H]([C@H](OC(=O)C=2C=NC=CC=2)[C@@H](COC(=O)C=2C=NC=CC=2)O1)OC(=O)C=1C=NC=CC=1)OC(=O)C1=CC=CN=C1 FUWFSXZKBMCSKF-ZASNTINBSA-N 0.000 description 5
- 150000006636 nicotinic acid Chemical class 0.000 description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical class COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 5
- 150000004102 olmesartan derivatives Chemical class 0.000 description 5
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical class C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 5
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical class N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical class C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 5
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical class N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 5
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical class [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 5
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical class C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical class C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical class CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical class COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical class C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical class N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 5
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical class C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 5
- AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical class C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 description 5
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 5
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical class CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical class C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 5
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical class N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 5
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical class C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical class C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 5
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 5
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical class CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- IGELFKKMDLGCJO-UHFFFAOYSA-N xenon difluoride Chemical compound F[Xe]F IGELFKKMDLGCJO-UHFFFAOYSA-N 0.000 description 5
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical class C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- BHZSLLSDZFAPFH-UHFFFAOYSA-L palladium(2+);difluoride Chemical compound F[Pd]F BHZSLLSDZFAPFH-UHFFFAOYSA-L 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000003682 fluorination reaction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 229960005461 torasemide Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical class [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960001264 benfluorex Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 150000003842 bromide salts Chemical class 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical class C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- 229960003564 cyclizine Drugs 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960001271 desloratadine Drugs 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- KQTXIZHBFFWWFW-UHFFFAOYSA-L disilver;carbonate Chemical compound [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical class O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 150000002466 imines Chemical group 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 229950008325 levothyroxine Drugs 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000002940 palladium Chemical class 0.000 description 2
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical class C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 239000002210 silicon-based material Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 229960001124 trientine Drugs 0.000 description 2
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- BLIQUJLAJXRXSG-UHFFFAOYSA-N 1-benzyl-3-(trifluoromethyl)pyrrolidin-1-ium-3-carboxylate Chemical group C1C(C(=O)O)(C(F)(F)F)CCN1CC1=CC=CC=C1 BLIQUJLAJXRXSG-UHFFFAOYSA-N 0.000 description 1
- JFZMMCYRTJBQQI-UHFFFAOYSA-M 1-fluoropyridin-1-ium;trifluoromethanesulfonate Chemical compound F[N+]1=CC=CC=C1.[O-]S(=O)(=O)C(F)(F)F JFZMMCYRTJBQQI-UHFFFAOYSA-M 0.000 description 1
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SQERDRRMCKKWIL-UHFFFAOYSA-N 2-hydroperoxy-2-oxoacetic acid Chemical compound OOC(=O)C(O)=O SQERDRRMCKKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000002077 Coxsackievirus Infections Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229910021605 Palladium(II) bromide Inorganic materials 0.000 description 1
- 229910021606 Palladium(II) iodide Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 229910021608 Silver(I) fluoride Inorganic materials 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010045276 Typhus infections Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- LHWMAHAYQHDDGY-UHFFFAOYSA-N [fluoro(hydroxy)boranyl]oxyboronic acid pyridine Chemical compound C1=CC=NC=C1.OB(O)OB(O)F.OB(O)OB(O)F.OB(O)OB(O)F.OB(O)OB(O)F.OB(O)OB(O)F.OB(O)OB(O)F.OB(O)OB(O)F LHWMAHAYQHDDGY-UHFFFAOYSA-N 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 208000037950 acute febrile pharyngitis Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000001501 aryl fluorides Chemical class 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UYANAUSDHIFLFQ-UHFFFAOYSA-N borinic acid Chemical group OB UYANAUSDHIFLFQ-UHFFFAOYSA-N 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical group FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000009846 hyperplastic epithelial lesion Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000037951 infantile gastroenteritis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910002094 inorganic tetrachloropalladate Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 229940030627 lipid modifying agent Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- PENAXHPKEVTBLF-UHFFFAOYSA-L palladium(2+);prop-1-ene;dichloride Chemical compound [Pd+]Cl.[Pd+]Cl.[CH2-]C=C.[CH2-]C=C PENAXHPKEVTBLF-UHFFFAOYSA-L 0.000 description 1
- RFLFDJSIZCCYIP-UHFFFAOYSA-L palladium(2+);sulfate Chemical compound [Pd+2].[O-]S([O-])(=O)=O RFLFDJSIZCCYIP-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 229910000364 palladium(II) sulfate Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 description 1
- INIOZDBICVTGEO-UHFFFAOYSA-L palladium(ii) bromide Chemical compound Br[Pd]Br INIOZDBICVTGEO-UHFFFAOYSA-L 0.000 description 1
- XDASSWBZWFFNPX-UHFFFAOYSA-N palladium(ii) cyanide Chemical compound [Pd+2].N#[C-].N#[C-] XDASSWBZWFFNPX-UHFFFAOYSA-N 0.000 description 1
- HNNUTDROYPGBMR-UHFFFAOYSA-L palladium(ii) iodide Chemical compound [Pd+2].[I-].[I-] HNNUTDROYPGBMR-UHFFFAOYSA-L 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000001369 pharyngoconjunctival fever Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000009331 reductive pathway Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 description 1
- KKKDGYXNGYJJRX-UHFFFAOYSA-M silver nitrite Chemical compound [Ag+].[O-]N=O KKKDGYXNGYJJRX-UHFFFAOYSA-M 0.000 description 1
- YDHABVNRCBNRNZ-UHFFFAOYSA-M silver perchlorate Chemical compound [Ag+].[O-]Cl(=O)(=O)=O YDHABVNRCBNRNZ-UHFFFAOYSA-M 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- NRUVOKMCGYWODZ-UHFFFAOYSA-N sulfanylidenepalladium Chemical compound [Pd]=S NRUVOKMCGYWODZ-UHFFFAOYSA-N 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- DAHWFTWPSFSFMS-UHFFFAOYSA-N trihydroxysilane Chemical compound O[SiH](O)O DAHWFTWPSFSFMS-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 1
- UKHQRARQNZOXRL-UHFFFAOYSA-N trimethyltin Chemical compound C[SnH](C)C UKHQRARQNZOXRL-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/38—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/31—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/31—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings
- C07C211/32—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings containing dibenzocycloheptane or dibenzocycloheptene ring systems or condensed derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
- C07C63/72—Polycyclic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/86—Ring systems containing bridged rings containing four rings
- C07C2603/88—Ethanoanthracenes; Hydrogenated ethanoanthracenes
Definitions
- Functionalized fluorine containing compounds e.g. aryl fluorides
- these products have favorable pharmacological properties such as desirable metabolic stability.
- fluorinated derivatives of compounds e.g., pharmaceutical agents
- exemplary pharmaceutical agents include a compound described herein or a fluorinated derivative thereof, such as a pharmaceutical agent described herein.
- the invention features a method of making a fluorinated compound, such as a compound described herein, using a method described herein.
- the invention features a fluorinated atazanavir, for example, a derivative of atazanavir wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated atazanavir has the following formula:
- the invention features a method of making a fluorinated atazanavir, for example, the fluorinated atazanavir shown above, using a method described herein.
- the invention features a fluorinated lopinavir, for example, a derivative of lopinavir wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated lopinavir is selected from one of the following:
- the invention features a method of making a fluorinated lopinavir, for example, a fluorinated lopinavir shown above, using a method described herein.
- the invention features a fluorinated ritonavir, for example, a derivative of ritonavir wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated ritonavir is selected from one of the following:
- the invention features a method of making a fluorinated ritonavir, for example, a fluorinated ritonavir shown above, using a method described herein.
- the invention features a fluorinated minocycline, for example, a derivative of minocycline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated minocycline has the following formula:
- the invention features a method of making a fluorinated minocycline, for example, the fluorinated minocycline shown above, using a method described herein.
- the invention features a fluorinated amoxicillin, for example, a derivative of amoxicillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated amoxicillin has the following formula:
- the invention features a method of making a fluorinated amoxicillin, for example, the fluorinated amoxicillin shown above, using a method described herein.
- the invention features a fluorinated cephalexin, for example, a derivative of cephalexin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cephalexin has the following formula:
- the invention features a method of making a fluorinated cephalexin, for example, the fluorinated cephalexin shown above, using a method described herein.
- the invention features a fluorinated vancomycin, for example, a derivative of vancomycin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated vancomycin has the following formula:
- the invention features a method of making a fluorinated vancomycin, for example, the fluorinated vancomycin shown above, using a method described herein.
- the invention features a fluorinated trimethoprim, for example, a derivative of trimethoprim wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated trimethoprim has the following formula:
- the invention features a method of making a fluorinated trimethoprim, for example, the fluorinated trimethoprim shown above, using a method described herein.
- the invention features a fluorinated cefadroxil, for example, a derivative of cefadroxil wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 19 F.
- the fluorinated cefadroxil has the following formula:
- the invention features a method of making a fluorinated cefadroxil, for example, the fluorinated cefadroxil shown above, using a method described herein.
- the invention features a fluorinated terconazole, for example, a derivative of terconazole wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated terconazole is selected from one of the following:
- the invention features a method of making a fluorinated terconazole, for example, the fluorinated terconazole shown above, using a method described herein.
- the invention features a fluorinated ampicillin, for example, a derivative of ampicillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated ampicillin has the following formula:
- the invention features a method of making a fluorinated ampicillin, for example, the fluorinated ampicillin shown above, using a method described herein.
- the invention features a fluorinated carbenicillin, for example, a derivative of carbenicillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated carbenicillin has the following formula:
- the invention features a method of making a fluorinated carbenicillin, for example, the fluorinated carbenicillin shown above, using a method described herein.
- the invention features a fluorinated cefaclor, for example, a derivative of cefaclor wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefaclor has the following formula:
- the invention features a method of making a fluorinated cefaclor, for example, the fluorinated cefaclor shown above, using a method described herein.
- the invention features a fluorinated cefamandole, for example, a derivative of cefamandole wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefamandole has the following formula:
- the invention features a method of making a fluorinated cefamandole, for example, the fluorinated cefamandole shown above, using a method described herein.
- the invention features a fluorinated cefixime, for example, a derivative of cefixime wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated cefixime has the following formula:
- the invention features a method of making a fluorinated cefixime, for example, the fluorinated cefixime shown above, using a method described herein.
- the invention features a fluorinated cefonicid, for example, a derivative of cefonicid wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefonicid has the following formula:
- the invention features a method of making a fluorinated cefonicid, for example, the fluorinated cefonicid shown above, using a method described herein.
- the invention features a fluorinated cefoperazone, for example, a derivative of cefoperazone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefoperazone has the following formula:
- the invention features a method of making a fluorinated cefoperazone, for example, the fluorinated cefoperazone shown above, using a method described herein.
- the invention features a fluorinated cefotaxime, for example, a derivative of cefotaxime wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefotaxime has the following formula:
- the invention features a method of making a fluorinated cefotaxime, for example, the fluorinated cefotaxime shown above, using a method described herein.
- the invention features a fluorinated cefoxitin, for example, a derivative of cefoxitin wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cefoxitin has the following formula:
- the invention features a method of making a fluorinated cefoxitin, for example, the fluorinated cefoxitin shown above, using a method described herein.
- the invention features a fluorinated ceftazidime, for example, a derivative of ceftazidime wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated ceftazidime has the following formula:
- the invention features a method of making a fluorinated ceftazidime, for example, the fluorinated ceftazidime shown above, using a method described herein.
- the invention features a fluorinated ceftriaxone, for example, a derivative of ceftriaxone wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated ceftriaxone has the following formula:
- the invention features a method of making a fluorinated ceftriaxone, for example, the fluorinated ceftriaxone shown above, using a method described herein.
- the invention features a fluorinated cephalothin, for example, a derivative of cephalothin wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cephalothin has the following formula:
- the invention features a method of making a fluorinated cephalothin, for example, the fluorinated cephalothin shown above, using a method described herein.
- the invention features a fluorinated methicillin, for example, a derivative of methicillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated methicillin has the following formula:
- the invention features a method of making a fluorinated methicillin, for example, the fluorinated methicillin shown above, using a method described herein.
- the invention features a fluorinated nafcillin, for example, a derivative of nafcillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated nafcillin has the following formula:
- the invention features a method of making a fluorinated nafcillin, for example, the fluorinated nafcillin shown above, using a method described herein.
- the invention features a fluorinated nalidixic acid, for example, a derivative of nalidixic acid wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methyl substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated nalidixic acid is selected from one of the following:
- the invention features a method of making a fluorinated nalidixic acid, for example, a fluorinated nalidixic acid shown above, using a method described herein.
- the invention features a fluorinated oxacillin, for example, a derivative of oxacillin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated oxacillin has the following formula:
- the invention features a method of making a fluorinated oxacillin, for example, the fluorinated oxacillin shown above, using a method described herein.
- the invention features a fluorinated piperacillin, for example, a derivative of piperacillin wherein an aryl group has been substituted with one or more
- the fluorinated piperacillin has the following formula:
- the invention features a method of making a fluorinated piperacillin, for example, the fluorinated piperacillin shown above, using a method described herein.
- the invention features a fluorinated rifampin, for example, a derivative of rifampin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated rifampin has the following formula:
- the invention features a method of making a fluorinated rifampin, for example, the fluorinated rifampin shown above, using a method described herein.
- the invention features a fluorinated sulfisoxazole, for example, a derivative of sulfisoxazole wherein an aryl group has been substituted with one or more
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated sulfisoxazole has the following formula:
- the invention features a method of making a fluorinated sulfisoxazole, for example, the fluorinated sulfisoxazole shown above, using a method described herein.
- the invention features a fluorinated ticarcillin, for example, a derivative of ticarcillin wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated ticarcillin has the following formula:
- the invention features a method of making a fluorinated ticarcillin, for example, the fluorinated ticarcillin shown above, using a method described herein.
- the invention features an 18 F- substituted terbinafine, for example, a derivative of terbinafine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted terbinafine has the following formula:
- the invention features a method of making a fluorinated terbinafine, for example, a fluorinated terbinafine with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted benzoyl peroxide, for example, a derivative of benzoyl peroxide wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted benzoyl peroxide has the following formula:
- the invention features a method of making a fluorinated benzoyl peroxide, for example, a fluorinated benzoyl peroxide with the following formula, using a method described herein:
- the invention features an 18 F- substituted efavirenz, for example, a derivative of efavirenz wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted efavirenz has the following formula:
- the invention features a method of making a fluorinated efavirenz, for example, a fluorinated efavirenz with the following formula, using a method described herein:
- the invention features a fluorinated doxycycline, for example, a derivative of doxycycline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorinated doxycycline does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated doxycycline is selected from one of the following:
- the invention features a method of making a fluorinated doxycycline, including any of the three fluorinated doxycycline structures shown above, using a method described herein.
- the invention features an 18 F- substituted doxycycline, for example, a derivative of doxycycline wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted doxycycline has the following formula:
- the invention features an 18 F- substituted clotrimazole, for example, a derivative of clotrimazole wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted clotrimazole has the following formula:
- the invention features a method of making a fluorinated clotrimazole, for example, a fluorinated clotrimazole with the following formula, using a method described herein:
- the invention features a fluorinated ketoconazole, for example, a derivative of ketoconazole wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been
- the fluorinated ketoconazole does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 1188 FF.. 1 In some embodiments, the fluorinated ketoconazole is selected from one of the following:
- the invention features a method of making a fluorinated ketoconazole, including any of the three fluorinated ketoconazole structures shown above, using a method described herein.
- the invention features an 18 F- substituted ketoconazole, for example, a derivative of ketoconazole wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted ketoconazole has the following formula:
- the invention features an 18 F- substituted hydroxychloroquine, for example, a derivative of hydroxychloroquine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has
- the 18 F- substituted hydroxychloroquine has the following formula:
- the invention features a method of making a fluorinated hydroxychloroquine, for example, a fluorinated hydroxychloroquine with the following formula, using a method described herein:
- the invention features a fluorinated itraconazole, for example, a derivative of itraconazole wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated itraconazole does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated itraconazole is selected from one of the following:
- the invention features a method of making a fluorinated itraconazole, including any of the three fluorinated itraconazole structures shown above, using a method described herein.
- the invention features an 18 F- substituted itraconazole, for example, a derivative of itraconazole wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted itraconazole has the following formula:
- cephalosporin for example, a derivative of cephalosporin wherein an aryl or heteroaryl group has been substituted with one
- the 18 F- substituted cephalosporin has the following formula:
- the invention features a method of making a fluorinated cephalosporin, for example, a fluorinated cephalosporin with the following formula, using a method described herein:
- the invention features a fluorinated tetracycline, for example, a derivative of tetracycline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorinated tetracycline does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated tetracycline is selected from one of the following:
- the invention features a method of making a fluorinated tetracycline, including any of the three fluorinated tetracycline structures shown above, using a method described herein.
- the invention features an 18 F- substituted tetracycline, for example, a derivative of tetracycline wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted tetracycline has the following formula:
- the invention features a fluorinated ramipril, for example, a derivative of ramipril wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated ramipril has the following formula:
- the invention features a method of making a fluorinated ramipril, for example, the fluorinated ramipril shown above, using a method described herein.
- the invention features a fluorinated losartan, for example, a derivative of losartan wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated losartan has the following formula:
- the invention features a method of making a fluorinated losartan, for example, the fluorinated losartan shown above, using a method described herein.
- the invention features a fluorinated olmesartan, for example, a derivative of olmesartan wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated olmesartan has the following formula:
- the invention features a method of making a fluorinated olmesartan, for example, the fluorinated olmesartan shown above, using a method described herein.
- the invention features a fluorinated candesartan, for example, a derivative of candesartan wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated candesartan is selected from one of the following:
- the invention features a method of making a fluorinated candesartan, for example, a fluorinated candesartan shown above, using a method described herein.
- the invention features a fluorinated felodipine, for example, a derivative of felodipine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated felodipine is selected from one of the following:
- the invention features a method of making a fluorinated felodipine, for example, a fluorinated felodipine shown above, using a method described herein.
- the invention features a fluorinated propranolol, for example, a derivative of propranolol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated propranolol has the following formula:
- the invention features a method of making a fluorinated propranolol, for example, the fluorinated propranolol shown above, using a method described herein.
- the invention features a fluorinated benazepril, for example, a derivative of benazepril wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated benazepril is selected from one of the following:
- the invention features a method of making a fluorinated benazepril, for example, a fluorinated benazepril shown above, using a method described herein.
- the invention features a fluorinated fosinopril, for example, a derivative of fosinopril wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated fosinopril has the following formula:
- the invention features a method of making a fluorinated fosinopril, for example, the fluorinated fosinopril shown above, using a method described herein.
- the invention features a fluorinated doxazosin, for example, a derivative of doxazosin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated doxazosin is selected from one of the following:
- the invention features a method of making a fluorinated doxazosin, for example, a fluorinated doxazosin shown above, using a method described herein.
- the invention features a fluorinated midodrine, for example, a derivative of midodrine wherein an aryl group has been substituted with one or more fluorine atoms,
- the fluorinated midodrine has the following formula:
- the invention features a method of making a fluorinated midodrine, for example, the fluorinated midodrine shown above, using a method described herein.
- the invention features an 18 F- substituted hydrochlorothiazide, for example, a derivative of hydrochlorothiazide wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F- substituted hydrochlorothiazide has the following formula:
- the invention features a method of making a fluorinated hydrochlorothiazide, for example, a fluorinated hydrochlorothiazide with the following formula, using a method described herein:
- the invention features an 18 F- substituted sildenafil, for example, a derivative of sildenafil wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F-substituted sildenafil has the following formula:
- the invention features a method of making a fluorinated sildenafil, for example, a fluorinated sildenafil with the following formula, using a method described herein:
- the invention features an 18 F- substituted amlodipine, for example, a derivative of amlodipine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted amlodipine has the following formula:
- the invention features a method of making a fluorinated amlodipine, for example, a fluorinated amlodipine with the following formula, using a method described herein:
- the invention features an 18 F- substituted tadalafil, for example, a derivative of tadalafil wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted tadalafil has the following formula:
- the invention features a method of making a fluorinated tadalafil, for example, a fluorinated tadalafil with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted lisinopril, for example, a derivative of lisinopril wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted lisinopril has the following formula:
- the invention features a method of making a fluorinated lisinopril, for example, a fluorinated lisinopril with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted nifedipine, for example, a derivative of nifedipine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or nitro substituent of an aryl group has been replaced with 18 F.
- the 18 F-substituted nifedipine has the following formula:
- the invention features a method of making a fluorinated nifedipine, for example, a fluorinated nifedipine with the following formula, using a method described herein:
- the invention features a fluorinated diltiazem, for example, a derivative of diltiazem wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorinated diltiazem does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated diltiazem is selected from one of the following:
- the invention features a method of making a fluorinated diltiazem, including any of the three fluorinated diltiazem structures shown above, using a method described herein.
- the invention features an 18 F- substituted diltiazem, for example, a derivative of diltiazem wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl group has been replaced with 18 F.
- the 18 F-substituted diltiazem has the following formula:
- the invention features a fluorinated quinapril, for example, a derivative of quinapril wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated quinapril does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated quinapril is selected from one of the following:
- the invention features a method of making a fluorinated quinapril, including any of the three fluorinated quinapril structures shown above, using a method described herein.
- the invention features an 18 ⁇ F-substituted quinapril, for example, a derivative of quinapril wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted quinapril has the following formula:
- the invention features an 18 ⁇ F-substituted enalapril, for example, a derivative of enalapril wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted enalapril has the following formula:
- the invention features a method of making a fluorinated enalapril, for example, a fluorinated enalapril with the following formula, using a method described herein:
- the invention features a fluorinated labetalol, for example, a derivative of labetalol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorinated labetalol does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated labetalol is selected from one of the following:
- the invention features a method of making a fluorinated labetalol, including any of the three fluorinated labetalol structures shown above, using a method described herein.
- the invention features an 18 F- substituted labetalol, for example, a derivative of labetalol wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted labetalol has the following formula:
- the invention features a fluorinated tiotropium, for example, a derivative of tiotropium wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated tiotropium has the following formula:
- the invention features a method of making a fluorinated tiotropium, for example, the fluorinated tiotropium shown above, using a method described herein.
- the invention features a fluorinated salbutamol, for example, a derivative of salbutamol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxyl substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated salbutamol has the following formula:
- the invention features a method of making a fluorinated salbutamol, for example, the fluorinated salbutamol shown above, using a method described herein.
- the invention features a fluorinated fexofenadine, for example, a derivative of fexofenadine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated fexofenadine is selected from one of the following:
- the invention features a method of making a fluorinated fexofenadine, for example, a fluorinated fexofenadine shown above, using a method described herein.
- the invention features a fluorinated eletriptan, for example, a derivative of eletriptan wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated eletriptan has the following formula:
- the invention features a method of making a fluorinated eletriptan, for example, the fluorinated eletriptan shown above, using a method described herein.
- the invention features a fluorinated nabumetone, for example, a derivative of nabumetone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated nabumetone has the following formula:
- the invention features a method of making a fluorinated nabumetone, for example, the fluorinated nabumetone shown above, using a method described herein.
- the invention features a fluorinated hydroxyzine, for example, a derivative of hydroxyzine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated hydroxyzine has the following formula:
- the invention features a method of making a fluorinated hydroxyzine, for example, the fluorinated hydroxyzine shown above, using a method described herein.
- the invention features a fluorinated promethazine, for example, a derivative of promethazine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated promethazine is selected from one of the following:
- the invention features a method of making a fluorinated promethazine, for example, a fluorinated promethazine shown above, using a method described herein.
- the invention features a fluorinated etodolac, for example, a derivative of etodolac wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated etodolac has the following formula:
- the invention features a method of making a fluorinated etodolac, for example, the fluorinated etodolac shown above, using a method described herein.
- the invention features a fluorinated albuterol, for example, a derivative of albuterol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated albuterol has the following formula:
- the invention features a method of making a fluorinated albuterol, for example, the fluorinated albuterol shown above, using a method described herein.
- the invention features a fluorinated ipratropium, for example, a derivative of ipratropium wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- a fluorinated ipratropium for example, a derivative of ipratropium wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated ipratropium has the following formula:
- the invention features a method of making a fluorinated ipratropium, for example, the fluorinated ipratropium shown above, using a method described herein.
- the invention features a fluorinated meclozine, for example, a derivative of meclozine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated meclozine is selected from one of the following:
- the invention features a method of making a fluorinated meclozine, for example, a fluorinated meclozine shown above, using a method described herein.
- the invention features a fluorinated tolfenamic acid, for example, a derivative of tolfenamic acid wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been
- the fluorine substituent is I9 ⁇ F.
- the fluorinated tolfenamic acid is selected from one of the following:
- the invention features a method of making a fluorinated tolfenamic acid, for example, a fluorinated tolfenamic acid shown above, using a method described herein.
- the invention features a fluorinated almotriptan, for example, a derivative of almotriptan wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated almotriptan has the following formula:
- the invention features a method of making a fluorinated almotriptan, for example, the fluorinated almotriptan shown above, using a method described herein.
- the invention features a fluorinated zolmitriptan, for example, a derivative of zolmitriptan wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated zolmitriptan has the following formula:
- the invention features a method of making a fluorinated zolmitriptan, for example, the fluorinated zolmitriptan shown above, using a method described herein.
- the invention features a fluorinated pizotifen, for example, a derivative of pizotifen wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated pizotifen has the following formula:
- the invention features a method of making a fluorinated pizotifen, for example, the fluorinated pizotifen shown above, using a method described herein.
- the invention features a fluorinated methysergide, for example, a derivative of methysergide wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated methysergide has the following formula:
- the invention features a method of making a fluorinated methysergide, for example, the fluorinated methysergide shown above, using a method described herein.
- the invention features a fluorinated montelukast, for example, a derivative of montelukast wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl ring has been replaced with a fluorine.
- the fluorinated montelukast does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated montelukast is selected from one of the following:
- the invention features a method of making a fluorinated montelukast, including any of the three fluorinated montelukast structures shown above, using a method described herein.
- the invention features an 18 F- substituted montelukast, for example, a derivative of montelukast wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted montelukast has the following formula:
- the invention features a method of making a fluorinated celecoxib, for example, a fluorinated celecoxib with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted cetirizine, for example, a derivative of cetirizine wherein an aryl group has been substituted with one or more 18 ⁇ F
- the 18 F- substituted cetirizine has the following formula:
- the invention features a method of making a fluorinated cetirizine, for example, a fluorinated cetirizine with the following formula, using a method described herein:
- the invention features an 18 F- substituted mesalazine, for example, a derivative of mesalazine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted mesalazine has the following formula:
- the invention features a method of making a fluorinated mesalazine, for example, a fluorinated mesalazine with the following formula, using a method described herein:
- the invention features an 18 F- substituted desloratadine, for example, a derivative of desloratadine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl
- the 18 F- substituted desloratadine has the following formula:
- the invention features a method of making a fluorinated desloratadine, for example, a fluorinated desloratadine with the following formula, using a method described herein:
- the invention features an 18 F- substituted azelastine, for example, a derivative of azelastine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted azelastine has the following formula:
- the invention features a method of making a fluorinated azelastine, for example, a fluorinated azelastine with the following formula, using a method described herein:
- the invention features an 18 F- substituted aspirin, for example, a derivative of aspirin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F- substituted aspirin has the following formula:
- the invention features a method of making a fluorinated aspirin, for example, a fluorinated aspirin with the following formula, using a method described herein:
- the invention features an 18 F- substituted rizatriptan, for example, a derivative of rizatriptan wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or a triazole substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted rizatriptan has the following formula:
- the invention features a method of making a fluorinated rizatriptan, for example, a fluorinated rizatriptan with the following formula, using a method described herein:
- the invention features an 18 F- substituted meloxicam, for example, a derivative of meloxicam wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted meloxicam has the following formula:
- the invention features a method of making a fluorinated meloxicam, for example, a fluorinated meloxicam with the following formula, using a method described herein:
- the invention features an 18 F- substituted naproxen, for example, a derivative of naproxen wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted naproxen has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated naproxen, for example, a fluorinated naproxen with the following formula, using a method described herein:
- the invention features an 18 F- substituted diclofenac, for example, a derivative of diclofenac wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or a halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted diclofenac is selected from one of the
- the invention features a method of making a fluorinated diclofenac, for example, a fluorinated diclofenac with any of the following formulae, using a method described herein:
- the invention features an 18 F- substituted indomethacin, for example, a derivative of indomethacin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or a halogen or alkoxy substituent of an aryl group has been replaced with 18 F.
- the 18 F-substituted indomethacin is selected from one of the following:
- the invention features a method of making a fluorinated indomethacin, for example, a fluorinated indomethacin with one of the following formulae, using a method described herein:
- the invention features an 1 1 8 8 ⁇ F- substituted cinnarizine, for example, a derivative of cinnarizine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted cinnarizine is selected from one of the following:
- the invention features a method of making a fluorinated cinnarizine, for example, a fluorinated cinnarizine with one of the following formulae, using a method described herein:
- the invention features an 18 ⁇ F-substituted cyclizine, for example, a derivative of cyclizine wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted cyclizine has the following formula:
- the invention features a method of making a fluorinated cyclizine, for example, a fluorinated cyclizine with the following formula, using a method described herein:
- the invention features a fluorinated ergotamine, for example, a derivative of ergotamine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated ergotamine does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated ergotamine is selected from one of the following:
- the invention features a method of making a fluorinated ergotamine, including any of the three fluorinated ergotamine structures shown above, using a method described herein.
- the invention features an 18 F- substituted ergotamine, for example, a derivative of ergotamine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted ergotamine has the following formula:
- the invention features a fluorinated carvedilol, for example, a derivative of carvedilol wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated carvedilol has the following formula:
- the invention features a method of making a fluorinated carvedilol, for example, the fluorinated carvedilol shown above, using a method described herein.
- the invention features a fluorinated metoprolol, for example, a derivative of metoprolol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated metoprolol has the following formula:
- the invention features a method of making a fluorinated metoprolol, for example, the fluorinated metoprolol shown above, using a method described herein.
- the invention features a fluorinated atenolol, for example, a derivative of atenolol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated atenolol has the following formula:
- the invention features a method of making a fluorinated atenolol, for example, the fluorinated atenolol shown above, using a method described herein.
- the invention features a fluorinated verapamil, for example, a derivative of verapamil wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated verapamil is selected from one of the following:
- the invention features a method of making a fluorinated verapamil, for example, a fluorinated verapamil shown above, using a method described herein.
- the invention features a fluorinated bisoprolol, for example, a derivative of bisoprolol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is
- the fluorinated bisoprolol has the following formula:
- the invention features a method of making a fluorinated bisoprolol, for example, the fluorinated bisoprolol shown above, using a method described herein.
- the invention features a fluorinated sotalol, for example, a derivative of sotalol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated sotalol has the following formula:
- the invention features a method of making a fluorinated sotalol, for example, the fluorinated sotalol shown above, using a method described herein.
- the invention features an 18 F- substituted clopidogrel, for example, a derivative of clopidogrel wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted clopidogrel has the following formula:
- the invention features a method of making a fluorinated clopidogrel, for example, a fluorinated clopidogrel with the following formula, using a method described herein:
- the invention features a fluorinated warfarin, for example, a derivative of warfarin wherein an aryl or heteroaryl group has been substituted with one or more
- the fluorinated warfarin does not have either of the following formulae:
- the fluorine substituent is 1 i 9 y ⁇ F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated warfarin has the following formula:
- the invention features a method of making a fluorinated warfarin, including any of the three fluorinated warfarin structures shown above, using a method described herein.
- the invention features an 18 F- substituted warfarin, for example, a derivative of warfarin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F- substituted warfarin has the following formula:
- the invention features a fluorinated venlafaxine, for example, a derivative of venlafaxine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated venlafaxine has the following formula:
- the invention features a method of making a fluorinated venlafaxine, for example, the fluorinated venlafaxine shown above, using a method described herein.
- the invention features a fluorinated duloxetine, for example, a derivative of duloxetine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated duloxetine has the following formula:
- the invention features a method of making a fluorinated duloxetine, for example, the fluorinated duloxetine shown above, using a method described herein.
- the invention features a fluorinated varenicline, for example, a derivative of varenicline wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated varenicline has the following formula:
- the invention features a method of making a fluorinated varenicline, for example, the fluorinated varenicline shown above, using a method described herein.
- the invention features a fluorinated atomoxetine, for example, a derivative of atomoxetine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated atomoxetine has the following formula:
- the invention features a method of making a fluorinated atomoxetine, for example, the fluorinated atomoxetine shown above, using a method described herein.
- the invention features a fluorinated sertraline, for example, a derivative of sertraline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated sertraline is selected from one of the following:
- the invention features a method of making a fluorinated sertraline, for example, a fluorinated sertraline shown above, using a method described herein.
- the invention features a fluorinated trazodone, for example, a derivative of trazodone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated trazodone has the following formula:
- the invention features a method of making a fluorinated trazodone, for example, the fluorinated trazodone shown above, using a method described herein.
- the invention features a fluorinated mirtazapine, for example, a derivative of mirtazapine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated mirtazapine has the following formula:
- the invention features a method of making a fluorinated mirtazapine, for example, the fluorinated mirtazapine shown above, using a method described herein.
- the invention features a fluorinated amitriptyline, for example, a derivative of amitriptyline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated amitriptyline has the following formula:
- the invention features a method of making a fluorinated amitriptyline, for example, the fluorinated amitriptyline shown above, using a method described herein.
- the invention features a fluorinated amoxapine, for example, a derivative of amoxapine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated amoxapine is selected from one of the following:
- the invention features a method of making a fluorinated amoxapine, for example, a fluorinated amoxapine shown above, using a method described herein.
- the invention features a fluorinated clomipramine, for example, a derivative of clomipramine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated clomipramine has the following formula:
- the invention features a method of making a fluorinated clomipramine, for example, the fluorinated clomipramine shown above, using a method described herein.
- the invention features a fluorinated imipramine, for example, a derivative of imipramine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated imipramine has the following formula:
- the invention features a method of making a fluorinated imipramine, for example, the fluorinated imipramine shown above, using a method described herein.
- the invention features a fluorinated nortriptyline, for example, a derivative of nortriptyline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated nortriptyline has the following formula:
- the invention features a method of making a fluorinated nortriptyline, for example, the fluorinated nortriptyline shown above, using a method described herein.
- the invention features a fluorinated trimipramine, for example, a derivative of trimipramine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated trimipramine has the following formula:
- the invention features a method of making a fluorinated trimipramine, for example, the fluorinated trimipramine shown above, using a method described herein.
- the invention features a fluorinated maprotiline, for example, a derivative of maprotiline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated maprotiline has the following formula:
- the invention features a method of making a fluorinated maprotiline, for example, the fluorinated maprotiline shown above, using a method described herein.
- the invention features a fluorinated nefazodone, for example, a derivative of nefazodone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated nefazodone is selected from one of the following:
- the invention features a method of making a fluorinated nefazodone, for example, a fluorinated nefazodone shown above, using a method described herein.
- the invention features a fluorinated sibutramine, for example, a derivative of sibutramine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated sibutramine has the following formula:
- the invention features a method of making a fluorinated sibutramine, for example, the fluorinated sibutramine shown above, using a method described herein.
- the invention features an 18 F- substituted bupropion, for example, a derivative of bupropion wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted bupropion has the following formula:
- the invention features a method of making a fluorinated bupropion, for example, a fluorinated bupropion with the following formula, using a method described herein:
- the invention features a fluorinated fluoxetine, for example, a derivative of fluoxetine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkyl substituent of an aryl group has been replaced with a fluorine.
- the fluorinated fluoxetine does not have either of the following formulae:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated fluoxetine has the following formula:
- the invention features a method of making a fluorinated fluoxetine, including any of the three fluorinated fluoxetine structures shown above, using a method described herein.
- the invention features an 18 F- substituted fluoxetine, for example, a derivative of fluoxetine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or alkyl substituent of an aryl group has been replaced with 18 F.
- the 18 F-substituted fluoxetine has the following formula:
- the invention features an 18 F-substituted citalopram, for example, a derivative of citalopram wherein an aryl group has been substituted with one or more 18 F
- the 18 F-substituted citalopram has the following formula:
- the invention features a method of making a fluorinated citalopram, for example, a fluorinated citalopram with the following formula, using a method described herein:
- the invention features an 18 F- substituted dosulepin, for example, a derivative of dosulepin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted dosulepin has the following formula:
- the invention features a method of making a fluorinated dosulepin, for example, a fluorinated dosulepin with the following formula, using a method described herein:
- the invention features a fluorinated doxepin, for example, a derivative of doxepin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorinated doxepin does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueent is 18 F. In some embodiments, the fluorinated doxepin is selected from one of the following:
- the invention features a method of making a fluorinated doxepin, including any of the three fluorinated doxepin structures shown above, using a method described herein.
- the invention features an 18 F- substituted doxepin, for example, a derivative of doxepin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the doxepin for example, a derivative of doxepin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the invention features a fluorinated lofepramine, for example, a derivative of lofepramine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated lofepramine does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated lofepramine is selected from one of the following:
- the invention features a method of making a fluorinated lofepramine, including any of the three fluorinated lofepramine structures shown above, using a method described herein.
- the invention features an 18 F- substituted lofepramine, for example, a derivative of lofepramine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted lofepramine has the following formula:
- the invention features a fluorinated mianserin, for example, a derivative of mianserin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorinated mianserin does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated mianserin is selected from one of the following:
- the invention features a method of making a fluorinated mianserin, including any of the three fluorinated mianserin structures shown above, using a method described herein.
- the invention features an 18 F- substituted mianserin, for example, a derivative of mianserin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted mianserin has the following formula:
- the invention features an 18 ⁇ F-substituted reboxetine, for example, a derivative of reboxetine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or an alkoxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted reboxetine is selected from one of the following:
- the invention features a method of making a fluorinated reboxetine, for example, a fluorinated reboxetine with the following formula, using a method described herein:
- the invention features a method of making a fluorinated tryptophan, for example, a fluorinated tryptophan with the following formula, using a method described herein:
- the invention features a fluorinated isocarboxazid, for example, a derivative of isocarboxazid wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated isocarboxazid has the following formula:
- the invention features a method of making a fluorinated isocarboxazid, for example, the fluorinated isocarboxazid shown above, using a method described herein.
- the invention features an 18 F- substituted phenelzine, for example, a derivative of phenelzine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted phenelzine has the following formula:
- the invention features a method of making a fluorinated phenelzine, for example, a fluorinated phenelzine with the following formula, using a method described herein:
- the invention features an 18 F- substituted tranylcypromine, for example, a derivative of tranylcypromine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted tranylcypromine has the following formula:
- the invention features a method of making a fluorinated tranylcypromine, for example, a fluorinated tranylcypromine with the following formula, using a method described herein:
- the invention features an 18 F- substituted moclobemide, for example, a derivative of moclobemide wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted moclobemide has the following formula:
- the invention features a method of making a fluorinated moclobemide, for example, a fluorinated moclobemide with the following formula, using a method described herein:
- the invention features a fluorinated fosphenytoin, for example, a derivative of fosphenytoin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated fosphenytoin is selected from one of the following:
- the invention features a method of making a fluorinated fosphenytoin, for example, a fluorinated fosphenytoin shown above, using a method described herein.
- the invention features a fluorinated tolterodine, for example, a derivative of tolterodine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated tolterodine has the following formula:
- the invention features a method of making a fluorinated tolterodine, for example, the fluorinated tolterodine shown above, using a method described herein.
- the invention features a fluorinated darifenacin, for example, a derivative of darifenacin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated darifenacin is selected from one of the following:
- the invention features a method of making a fluorinated darifenacin, for example, a fluorinated darifenacin shown above, using a method described herein.
- the invention features a fluorinated oxcarbazepine, for example, a derivative of oxcarbazepine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated oxcarbazepine has the following formula:
- the invention features a method of making a fluorinated oxcarbazepine, for example, the fluorinated oxcarbazepine shown above, using a method described herein.
- the invention features a fluorinated cabergoline, for example, a derivative of cabergoline wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated cabergoline has the following formula:
- the invention features a method of making a fluorinated cabergoline, for example, the fluorinated cabergoline shown above, using a method described herein.
- the invention features a fluorinated benserazide, for example, a derivative of benserazide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated benserazide is selected from one of the following:
- the invention features a method of making a fluorinated benserazide, for example, a fluorinated benserazide shown above, using a method described herein.
- the invention features a fluorinated bromocriptine, for example, a derivative of bromocriptine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated bromocriptine has the following formula:
- the invention features a method of making a fluorinated bromocriptine, for example, the fluorinated bromocriptine shown above, using a method described herein.
- the invention features a fluorinated entacapone, for example, a derivative of entacapone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated entacapone has the following formula:
- the invention features a method of making a fluorinated entacapone, for example, the fluorinated entacapone shown above, using a method described herein.
- the invention features a fluorinated lisuride, for example, a derivative of lisuride wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated lisuride has the following formula:
- the invention features a method of making a fluorinated lisuride, for example, the fluorinated lisuride shown above, using a method described herein.
- the invention features a fluorinated pergolide, for example, a derivative of pergolide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated pergolide has the following formula:
- the invention features a method of making a fluorinated pergolide, for example, the fluorinated pergolide shown above, using a method described herein.
- the invention features a fluorinated biperiden, for example, a derivative of biperiden wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated biperiden has the following formula:
- the invention features a method of making a fluorinated biperiden, for example, the fluorinated biperiden shown above, using a method described herein.
- the invention features a fluorinated orphenadrine, for example, a derivative of orphenadrine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated orphenadrine is selected from one of the following:
- the invention features a method of making a fluorinated orphenadrine, for example, a fluorinated orphenadrine shown above, using a method described herein.
- the invention features a fluorinated procyclidine, for example, a derivative of procyclidine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated procyclidine has the following formula:
- the invention features a method of making a fluorinated procyclidine, for example, the fluorinated procyclidine shown above, using a method described herein.
- the invention features a fluorinated tetrabenazine, for example, a derivative of tetrabenazine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated tetrabenazine has the following formula:
- the invention features a method of making a fluorinated tetrabenazine, for example, the fluorinated tetrabenazine shown above, using a method described herein.
- the invention features an 18 F- substituted lamotrigine, for example, a derivative of lamotrigine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted lamotrigine has the following formula:
- the invention features a method of making a fluorinated lamotrigine, for example, a fluorinated lamotrigine with the following formula, using a method described herein:
- the invention features an 18 F- substituted solifenacin, for example, a derivative of solifenacin wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted solifenacin has the following formula:
- the invention features a method of making a fluorinated solifenacin, for example, a fluorinated solifenacin with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted clonazepam, for example, a derivative of clonazepam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted clonazepam has the following formula:
- the invention features a method of making a fluorinated clonazepam, for example, a fluorinated clonazepam with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted phenytoin, for example, a derivative of phenytoin wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted phenytoin is selected from one of the following:
- the invention features a method of making a fluorinated phenytoin, for example, a fluorinated phenytoin with either of the following formulae, using a method described herein:
- the invention features a fluorinated carbidopa, for example, a derivative of carbidopa wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated carbidopa has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated carbidopa, for example, the fluorinated carbidopa shown above.
- the invention features an 18 F- substituted levodopa, for example, a derivative of levodopa wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted levodopa has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated levodopa, for example, a fluorinated levodopa with the following formula, using a method described herein:
- the invention features an 18 F- substituted baclofen, for example, a derivative of baclofen wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted baclofen has the following formula:
- the invention features a method of making a fluorinated baclofen, for example, a fluorinated baclofen with the following formula, using a method described herein:
- the invention features an 18 F- substituted zonisamide, for example, a derivative of zonisamide wherein an aryl group has been substituted with one or more 18 F
- the 18 F-substituted zonisamide has the following formula:
- the invention features a method of making a fluorinated zonisamide, for example, a fluorinated zonisamide with the following formula, using a method described herein:
- the invention features an 18 F- substituted primidone, for example, a derivative of primidone wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted primidone has the following formula:
- the invention features a fluorinated domperidone, for example, a derivative of domperidone wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated domperidone does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 1188 FF.. 1 In some embodiments, the fluorinated domperidone is selected from one of the following:
- the invention features a method of making a fluorinated domperidone, including any of the three fluorinated domperidone structures shown above, using a method described herein.
- the invention features an 18 F- substituted domperidone, for example, a derivative of domperidone wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted domperidone has the following formula:
- the invention features an 18 F-substituted phenobarbital, for example, a derivative of phenobarbital wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted phenobarbital has the following formula:
- the invention features a method of making a fluorinated phenobarbital, for example, a fluorinated phenobarbital with the following formula, using a method described herein:
- the invention features a fluorinated clobazam, for example, a derivative of clobazam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated clobazam does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated clobazam is selected from one of the following:
- the invention features a method of making a fluorinated clobazam, including any of the three fluorinated clobazam structures shown above, using a method described herein.
- the invention features an 18 F- substituted clobazam, for example, a derivative of clobazam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted clobazam has the following formula:
- the invention features a method of making a fluorinated selegiline, for example, a fluorinated selegiline with the following formula, using a method described herein:
- the invention features an 18 F-substituted benzatropine, for example, a derivative of benzatropine wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted benzatropine is selected from one of the following:
- the invention features a method of making a fluorinated benzatropine, for example, a fluorinated benzatropine with one of the following formulae, using a method described herein:
- the invention features an 18 F-substituted trihexyphenidyl, for example, a derivative of trihexyphenidyl wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted trihexyphenidyl has the following formula:
- the invention features a method of making a fluorinated trihexyphenidyl, for example, a fluorinated trihexyphenidyl with the following formula, using a method described herein:
- the invention features an 18 F- substituted riluzole, for example, a derivative of riluzole wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or haloalkoxy of an aryl group has been replaced with 18 F.
- the 18 F-substituted riluzole has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated riluzole, for example, a fluorinated riluzole with the following formula, using a method described herein:
- the invention features a fluorinated aripiprazole, for example, a derivative of aripiprazole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- a fluorinated aripiprazole for example, a derivative of aripiprazole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine for example, a derivative of aripiprazole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl
- the fluorinated aripiprazole has the following formula:
- the invention features a method of making a fluorinated aripiprazole, for example, the fluorinated aripiprazole shown above, using a method described herein.
- the invention features a fluorinated olanzapine, for example, a derivative of olanzapine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated olanzapine has the following formula:
- the invention features a method of making a fluorinated olanzapine, for example, the fluorinated olanzapine shown above, using a method described herein.
- the invention features a fluorinated eszopiclone, for example, a derivative of eszopiclone wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated eszopiclone has the following formula:
- the invention features a method of making a fluorinated eszopiclone, for example, the fluorinated eszopiclone shown above, using a method described herein.
- the invention features a fluorinated alprazolam, for example, a derivative of alprazolam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated alprazolam is selected from one of the following:
- the invention features a method of making a fluorinated alprazolam, for example, a fluorinated alprazolam shown above, using a method described herein.
- the invention features a fluorinated flunitrazepam, for example, a derivative of flunitrazepam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated flunitrazepam has the following formula:
- the invention features a method of making a fluorinated flunitrazepam, for example, the fluorinated flunitrazepam shown above, using a method described herein.
- the invention features a fluorinated flurazepam, for example, a derivative of flurazepam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated flurazepam is selected from one of the following:
- the invention features a method of making a fluorinated flurazepam, for example, a fluorinated flurazepam shown above, using a method described herein.
- the invention features a fluorinated zaleplon, for example, a derivative of zaleplon wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- a fluorinated zaleplon for example, a derivative of zaleplon wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated zaleplon has the following formula:
- the invention features a method of making a fluorinated zaleplon, for example, the fluorinated zaleplon shown above, using a method described herein.
- the invention features a fluorinated clomethiazole, for example, a derivative of clomethiazole wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkyl substituent of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated clomethiazole has the following formula:
- the invention features a method of making a fluorinated clomethiazole, for example, the fluorinated clomethiazole shown above, using a method described herein.
- the invention features a fluorinated chlordiazepoxide, for example, a derivative of chlordiazepoxide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated chlordiazepoxide is selected from one of the following:
- the invention features a method of making a fluorinated chlordiazepoxide, for example, a fluorinated chlordiazepoxide shown above, using a method described herein.
- the invention features a fluorinated clorazepate, for example, a derivative of clorazepate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated clorazepate is selected from one of the following:
- the invention features a method of making a fluorinated clorazepate, for example, a fluorinated clorazepate shown above, using a method described herein.
- the invention features a fluorinated oxazepam, for example, a derivative of oxazepam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated oxazepam is selected from one of the following:
- the invention features a method of making a fluorinated oxazepam, for example, a fluorinated oxazepam shown above, using a method described herein.
- the invention features a fluorinated pericyazine, for example, a derivative of pericyazine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or cyano substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated pericyazine has the following formula:
- the invention features a method of making a fluorinated pericyazine, for example, the fluorinated pericyazine shown above, using a method described herein.
- the invention features a fluorinated sulpiride, for example, a derivative of sulpiride wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated sulpiride has the following formula:
- the invention features a method of making a fluorinated sulpiride, for example, the fluorinated sulpiride shown above, using a method described herein.
- the invention features a fluorinated thioridazine, for example, a derivative of thioridazine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or thioether substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated thioridazine has the following formula:
- the invention features a method of making a fluorinated thioridazine, for example, the fluorinated thioridazine shown above, using a method described herein.
- the invention features a fluorinated zuclopenthixol, for example, a derivative of zuclopenthixol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated zuclopenthixol has the following formula:
- the invention features a method of making a fluorinated zuclopenthixol, for example, the fluorinated zuclopenthixol shown above, using a method described herein.
- the invention features a fluorinated amisulpride, for example, a derivative of amisulpride wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated amisulpride has the following formula:
- the invention features a method of making a fluorinated amisulpride, for example, the fluorinated amisulpride shown above, using a method described herein.
- the invention features a fluorinated zotepine, for example, a derivative of zotepine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated zotepine has the following formula:
- the invention features a method of making a fluorinated zotepine, for example, the fluorinated zotepine shown above, using a method described herein.
- the invention features a fluorinated flupentixol, for example, a derivative of flupentixol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or haloalkyl substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated flupentixol has the following formula:
- the invention features a method of making a fluorinated flupentixol, for example, the fluorinated flupentixol shown above, using a method described herein.
- the invention features a fluorinated pipotiazine palmitate, for example, a derivative of pipotiazine palmitate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated pipotiazine palmitate has the following formula:
- the invention features a method of making a fluorinated pipotiazine palmitate, for example, the fluorinated pipotiazine palmitate shown above, using a method described herein.
- the invention features a fluorinated carbamazepine, for example, a derivative of carbamazepine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated carbamazepine is selected from one of the following:
- the invention features a method of making a fluorinated carbamazepine, for example, a fluorinated carbamazepine shown above, using a method described herein.
- the invention features a fluorinated galantamine, for example, a derivative of galantamine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated galantamine has the following formula:
- the invention features a method of making a fluorinated galantamine, for example, the fluorinated galantamine shown above, using a method described herein.
- the invention features a fluorinated rivastigmine, for example, a derivative of rivastigmine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated rivastigmine is selected from one of the following:
- the invention features a method of making a fluorinated rivastigmine, for example, a fluorinated rivastigmine shown above, using a method described herein.
- the invention features a fluorinated quetiapine, for example, a derivative of quetiapine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated quetiapine does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated quetiapine is selected from one of the following:
- the invention features a method of making a fluorinated quetiapine, including any of the three fluorinated quetiapine structures shown above, using a method described herein.
- the invention features an 18 F- substituted quetiapine, for example, a derivative of quetiapine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted quetiapine has the following formula:
- the invention features an 18 F- substituted lamotrigine, for example, a derivative of lamotrigine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted lamotrigine has the following formula:
- the invention features a method of making a fluorinated lamotrigine, for example, a fluorinated lamotrigine with the following formula, using a method described herein:
- the invention features a method of making a fluorinated amphetamine, for example, a fluorinated amphetamine with the following formula, using a method described herein:
- the invention features an 18 F- substituted methylphenidate, for example, a derivative of methylphenidate wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted methylphenidate has the following formula:
- the invention features a method of making a fluorinated methylphenidate, for example, a fluorinated methylphenidate with the following formula, using a method described herein:
- the invention features a method of making a fluorinated donepezil, for example, a fluorinated donepezil with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted Zolpidem, for example, a derivative of Zolpidem wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted Zolpidem has the following formula:
- the invention features a method of making a fluorinated Zolpidem, for example, a fluorinated Zolpidem with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted modafinil, for example, a derivative of modafinil wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted modafinil has the following formula:
- the invention features a method of making a fluorinated modafinil, for example, a fluorinated modafinil with the following formula, using a method described herein:
- the invention features an 18 F- substituted ziprasidone, for example, a derivative of ziprasidone wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted ziprasidone has the following formula:
- the invention features a method of making a fluorinated ziprasidone, for example, a fluorinated ziprasidone with the following formula, using a method described herein:
- the invention features a fluorinated lorazepam, for example, a derivative of lorazepam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated lorazepam does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated lorazepam is selected from one of the following:
- the invention features a method of making a fluorinated lorazepam, including any of the four fluorinated lorazepam structures shown above, using a method described herein.
- the invention features an 18 F- substituted lorazepam, for example, a derivative of lorazepam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted lorazepam has the following formula:
- the invention features an 18 F-substituted clonazepam, for example, a derivative of clonazepam wherein an aryl group has been substituted with one or more 18 ⁇ F
- the 18 F- substituted clonazepam has the following formula:
- the invention features a method of making a fluorinated clonazepam, for example, a fluorinated clonazepam with the following formula, using a method described herein:
- the invention features an 18 F- substituted diazepam, for example, a derivative of diazepam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted diazepam has the following formula:
- the invention features a method of making a fluorinated diazepam, for example, a fluorinated diazepam with the following formula, using a method described herein:
- the invention features an 18 F- substituted clozapine, for example, a derivative of clozapine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted clozapine has the following formula:
- the invention features a method of making a fluorinated clozapine, for example, a fluorinated clozapine with the following formula, using a method described herein:
- the invention features a fluorinated temazepam, for example, a derivative of temazepam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated temazepam does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated temazepam is selected from one of the following:
- the invention features a method of making a fluorinated temazepam, including any of the three fluorinated temazepam structures shown above, using a method described herein.
- the invention features an 18 F- substituted temazepam, for example, a derivative of temazepam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted temazepam has the following formula:
- the invention features a method of making a fluorinated dextroamphetamine, for example, a fluorinated dextroamphetamine with the following formula, using a method described herein:
- the invention features an 18 F- substituted nitrazepam, for example, a derivative of nitrazepam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted nitrazepam has the following formula:
- the invention features a method of making a fluorinated nitrazepam, for example, a fluorinated nitrazepam with the following formula, using a method described herein:
- the invention features a fluorinated loprazolam, for example, a derivative of loprazolam wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated loprazolam does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated loprazolam is selected from one of the following:
- the invention features a method of making a fluorinated loprazolam, including any of the three fluorinated loprazolam structures shown above, using a method described herein.
- the invention features an 18 F- substituted loprazolam, for example, a derivative of loprazolam wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted loprazolam has the following formula:
- the invention features an 18 ⁇ F-substituted buspirone, for example, a derivative of buspirone wherein a heteroaryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted buspirone has the following formula:
- the invention features a method of making a fluorinated buspirone, for example, a fluorinated buspirone with the following formula, using a method described herein:
- the invention features a fluorinated benperidol, for example, a derivative of benperidol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorinated benperidol does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated benperidol is selected from one of the following:
- the invention features a method of making a fluorinated benperidol, including any of the three fluorinated benperidol structures shown above, using a method described herein.
- the invention features an 18 F- substituted benperidol, for example, a derivative of benperidol wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted benperidol is selected from one of the following:
- the invention features an 18 F- substituted chlorpromazine or an 18 F- substituted promazine, for example, a derivative of chlorpromazine or promazine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or a halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted chlorpromazine or promazine has the following formula:
- the invention features a method of making a fluorinated chlorpromazine or a fluorinated promazine, for example, a fluorinated chlorpromazine or fluorinated promazine with the following formula, using a method described herein:
- the invention features an 18 F- substituted fluphenazine or an 18 F- substituted perphenazine, for example, a derivative of fluphenazine or perphenazine wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen, a halogen substituent or a haloalkyl substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted fluphenazine or 18 F- substituted perphenazine has the following formula:
- the invention features a method of making a fluorinated fluphenazine or a fluorinated perphenazine, for example, a fluorinated fluphenazine or fluorinated perphenazine with the following formula, using a method described herein:
- the invention features an 18 F- substituted haloperidol, for example, a derivative of haloperidol wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or a halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted haloperidol has the following formula:
- the invention features a method of making a fluorinated haloperidol, for example, a fluorinated haloperidol with one of the following formulae, using a method described herein:
- the invention features an 1 1 8 8 ⁇ F- substituted methotrimeprazine, for example, a derivative of methotrimeprazine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or an alkoxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted methotrimeprazine has the following formula:
- the invention features a method of making a fluorinated methotrimeprazine, for example, a fluorinated methotrimeprazine with the following formula, using a method described herein:
- the invention features a fluorinated loxapine, for example, a derivative of loxapine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group
- the fluorinated loxapine does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated loxapine is selected from one of the following:
- the invention features a method of making a fluorinated loxapine, including any of the seven fluorinated loxapine structures shown above, using a method described herein.
- the invention features an 18 F- substituted loxapine, for example, a derivative of loxapine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted loxapine has the following formula:
- the invention features a fluorinated oxypertine, for example, a derivative of oxypertine wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated oxypertine does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated oxypertine is selected from one of the following:
- the invention features a method of making a fluorinated oxypertine, including any of the three fluorinated oxypertine structures shown above, using a method described herein.
- the invention features an 18 F- substituted oxypertine, for example, a derivative of oxypertine wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F-substituted oxypertine has the following formula:
- the invention features a fluorinated pimozide, for example, a derivative of pimozide wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated pimozide does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated pimozide is selected from one of the following:
- the invention features a method of making a fluorinated pimozide, including any of the three fluorinated pimozide structures shown above, using a method described herein.
- the invention features an 18 F- substituted pimozide, for example, a derivative of pimozide wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted pimozide has the following formula:
- the 18 F- substituted prochlorperazine or 18 F- substituted trifluoperazine has the following formula:
- the invention features a method of making a fluorinated prochlorperazine or a fluorinated trifluoperazine, for example, a fluorinated prochlorperazine or a fluorinated trifluoperazine with the following formula, using a method described herein:
- the invention features an 18 F- substituted benzodiazepine, for example, a derivative of benzodiazepine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted benzodiazepine is selected from one of the following:
- the invention features a method of making a fluorinated benzodiazepine, for example, a fluorinated benzodiazepine with one of the following formulae, using a method described herein:
- the invention features a fluorinated metaxalone, for example, a derivative of metaxalone wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkyl substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated metaxalone is selected from one of the following:
- the invention features a method of making a fluorinated metaxalone, for example, a fluorinated metaxalone shown above, using a method described herein.
- the invention features a fluorinated tizanidine, for example, a derivative of tizanidine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated tizanidine has the following formula:
- the invention features a method of making a fluorinated tizanidine, for example, the fluorinated tizanidine shown above, using a method described herein.
- the invention features a fluorinated benzonatate, for example, a derivative of benzonatate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkylamino substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated benzonatate has the following formula:
- the invention features a method of making a fluorinated benzonatate, for example, the fluorinated benzonatate shown above, using a method described herein.
- the invention features an 18 F- substituted lidocaine, for example, a derivative of lidocaine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted lidocaine has the following formula:
- the invention features a method of making a fluorinated lidocaine, for example, a fluorinated lidocaine with the following formula, using a method described herein:
- the invention features an 18 F- substituted acetaminophen, for example, a derivative of acetaminophen wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted acetaminophen has the following formula:
- the invention features a method of making a fluorinated acetaminophen, for example, a fluorinated acetaminophen with the following formula, using a method described herein:
- the invention features a fluorinated tramadol, for example, a derivative of tramadol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorinated tramadol does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated tramadol has the following formula:
- the invention features a method of making a fluorinated tramadol, including either of the two fluorinated tramadol structures shown above, using a method described herein.
- the invention features an 18 F- substituted tramadol, for example, a derivative of tramadol wherein an aryl group has been substituted with one or more 18 F
- the 18 F-substituted tramadol has the following formula:
- the invention features a fluorinated ketamine, for example, a derivative of ketamine wherein an aryl group has been substituted with one or more fluorine atom, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorinated ketamine does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated ketamine is selected from one of the following:
- the invention features a method of making a fluorinated ketamine, including any of the three fluorinated ketamine structures shown above, using a method described herein.
- the invention features an 18 F- substituted ketamine, for example, a derivative of ketamine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted ketamine has the following formula:
- the invention features a fluorinated lansoprazole, for example, a derivative of lansoprazole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated lansoprazole has the following formula:
- the invention features a method of making a fluorinated lansoprazole, for example, the fluorinated lansoprazole shown above, using a method described herein.
- the invention features a fluorinated rabeprazole, for example, a derivative of rabeprazole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated rabeprazole has the following formula:
- the invention features a method of making a fluorinated rabeprazole, for example, the fluorinated rabeprazole shown above, using a method described herein.
- the invention features a fluorinated tamsulosin, for example, a derivative of tamsulosin wherein an aryl or heteroaryl group has been substituted with one or
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated tamsulosin has the following formula:
- the invention features a method of making a fluorinated tamsulosin, for example, the fluorinated tamsulosin shown above, using a method described herein.
- the invention features a fluorinated ethinyl estradiol, for example, a derivative of ethinyl estradiol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxyl substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated ethinyl estradiol has the following formula:
- the invention features a method of making a fluorinated ethinyl estradiol, for example, the fluorinated ethinyl estradiol shown above, using a method described herein.
- the invention features a fluorinated imiquimod, for example, a derivative of imiquimod wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 ⁇ F.
- the fluorinated imiquimod has the following formula:
- the invention features a method of making a fluorinated imiquimod, for example, the fluorinated imiquimod shown above, using a method described herein.
- the invention features a fluorinated cinacalcet, for example, a derivative of cinacalcet wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated cinacalcet has the following formula:
- the invention features a method of making a fluorinated cinacalcet, for example, the fluorinated cinacalcet shown above, using a method described herein.
- the invention features a fluorinated olopatadine, for example, a derivative of olopatadine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated olopatadine has the following formula:
- the invention features a method of making a fluorinated olopatadine, for example, the fluorinated olopatadine shown above, using a method described herein.
- the invention features a fluorinated bimatoprost, for example, a derivative of bimatoprost wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated bimatoprost has the following formula:
- the invention features a method of making a fluorinated bimatoprost, for example, the fluorinated bimatoprost shown above, using a method described herein.
- the invention features a fluorinated adapalene, for example, a derivative of adapalene wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated adapalene has the following formula:
- the invention features a method of making a fluorinated adapalene, for example, the fluorinated adapalene shown above, using a method described herein.
- the invention features a fluorinated brimonidine, for example, a derivative of brimonidine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated brimonidine has the following formula:
- the invention features a method of making a fluorinated brimonidine, for example, the fluorinated brimonidine shown above, using a method described herein.
- the invention features a fluorinated furosemide, for example, a derivative of furosemide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated furosemide has the following formula:
- the invention features a method of making a fluorinated furosemide, for example, the fluorinated furosemide shown above, using a method described herein.
- the invention features a fluorinated terazosin, for example, a derivative of terazosin wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated terazosin methadone is selected from one of the following:
- the invention features a method of making a fluorinated terazosin, for example, a fluorinated terazosin shown above, using a method described herein.
- the invention features a fluorinated metolazone, for example, a derivative of metolazone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated metolazone has the following formula:
- the invention features a method of making a fluorinated metolazone, for example, the fluorinated metolazone shown above, using a method described herein.
- the invention features an 18 F- substituted esomeprazole, for example, a derivative of esomeprazole wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or methoxy substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted esomeprazole has the following formula:
- the invention features a method of making a fluorinated esomeprazole, for example, a fluorinated esomeprazole with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted mycophenolic acid, for example, a derivative of mycophenolic acid wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted mycophenolic acid has the following formula:
- the invention features a method of making a fluorinated mycophenolic acid, for example, a fluorinated mycophenolic acid with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted estrone (e.g., a component of Premann), for example, a derivative of estrone wherein an aryl group has been substituted
- estrone e.g., a component of Premann
- the 18 F-substituted estrone has the following formula:
- the invention features a method of making a fluorinated estrone, for example, a fluorinated estrone with the following formula, using a method described herein:
- the invention features an 18 F- substituted levothyroxine, for example, a derivative of levothyroxine wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced wwiitthh 1188 FF.
- the 18 F- substituted levothyroxine is selected from one of the following:
- the invention features a method of making a fluorinated levothyroxine, for example, a fluorinated levothyroxine with one of the following formulae, using a method described herein:
- the invention features a fluorinated omeprazole, for example, a derivative of omeprazole wherein a heteroaryl has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkoxy substituent of a heteroaryl group has been replaced
- the fluorinated omeprazole does not have the following formula:
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated omeprazole has the following formula:
- the invention features a method of making a fluorinated omeprazole, including either of the two fluorinated omeprazole structures shown above, using a method described herein.
- the invention features an 18 F- substituted omeprazole, for example, a derivative of omeprazole wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or alkoxy substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F-substituted omeprazole has the following formula:
- the invention features an 18 F- substituted ondansetron, for example, a derivative of ondansetron wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted ondansetron has the following formula:
- the invention features a method of making a fluorinated ondansetron, for example, a fluorinated ondansetron with the following formula, using a method described herein:
- the invention features an 18 F- substituted metoclopramide, for example, a derivative of metoclopramide wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted metoclopramide has the following formula:
- the invention features a method of making a fluorinated metoclopramide, for example, a fluorinated metoclopramide with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted torsemide, for example, a derivative of torsemide wherein an aryl group has been substituted with one or more 18 ⁇ F
- the 18 F-substituted torsemide has the following formula:
- the invention features a method of making a torsemide, for example, a fluorinated torsemide with the following formula, using a method described herein:
- the invention features an 18 F- substituted estradiol, for example, a derivative of estradiol wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted estradiol has the following formula:
- the invention features a method of making a fluorinated estradiol, for example, a fluorinated estradiol with the following formula, using a method described herein:
- the invention features a method of making a fluorinated nicotine, for example, a fluorinated nicotine with the following formula, using a method described herein:
- the invention features a fluorinated ezetimibe, for example, a derivative of ezetimibe wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxyl substituent of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F.
- the fluorine substituent is 18 F.
- the fluorinated ezetimibe has the following formula:
- the invention features a method of making a fluorinated ezetimibe, for example, the fluorinated ezetimibe shown above, using a method described herein.
- the invention features a fluorinated gemfibrozil, for example, a derivative of gemfibrozil wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated gemfibrozil has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated gemfibrozil, for example, the fluorinated gemfibrozil shown above, using a method described herein.
- the invention features a fluorinated simfibrate, for example, a derivative of simfibrate wherein an aryl group has been substituted with one or more fluorine atoms,
- the fluorinated simfibrate is selected from one of the following:
- the invention features a method of making a fluorinated simfibrate, for example, a fluorinated simfibrate shown above, using a method described herein.
- the invention features a fluorinated ronifibrate, for example, a derivative of ronifibrate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments,
- the fluorine substituent is 18 ⁇ F.
- the fluorinated ronifibrate is selected from one of the following:
- the invention features a method of making a fluorinated ronifibrate, for example, a fluorinated ronifibrate shown above, using a method described herein.
- the invention features a fluorinated ciprofibrate, for example, a derivative of ciprofibrate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated ciprofibrate has the following formula:
- the invention features a method of making a fluorinated ciprofibrate, for example, the fluorinated ciprofibrate shown above, using a method described herein.
- the invention features a fluorinated clofibride, for example, a derivative of clofibride wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the
- the fluorinated clofibride is selected from one of the following:
- the invention features a method of making a fluorinated clofibride, for example, a fluorinated clofibride shown above, using a method described herein.
- the invention features a fluorinated nicofuranose, for example, a derivative of nicofuranose wherein a heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated nicofuranose is selected from one of the following:
- the invention features a method of making a fluorinated nicofuranose, for example, a fluorinated nicofuranose shown above, using a method described herein.
- the invention features a fluorinated dextrothyroxine, for example, a derivative of dextrothyroxine wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen, halogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated dextrothyroxine is selected from one of the following:
- the invention features a method of making a fluorinated dextrothyroxine, for example, a fluorinated dextrothyroxine shown above, using a method described herein.
- the invention features a fluorinated pyridoxal 5 '-phosphate, for example, a derivative of pyridoxal 5 '-phosphate wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated pyridoxal 5 '-phosphate has the following formula:
- the invention features a method of making a fluorinated pyridoxal 5'- phosphate, for example, the fluorinated pyridoxal 5 '-phosphate shown above, using a method described herein.
- the invention features a fluorinated pioglitazone, for example, a derivative of pioglitazone wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated pioglitazone has the following formula:
- the invention features a method of making a fluorinated pioglitazone, for example, the fluorinated pioglitazone shown above, using a method described herein.
- the invention features a fluorinated rosiglitazone, for example, a derivative of rosiglitazone wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated rosiglitazone has the following formula:
- the invention features a method of making a fluorinated rosiglitazone, for example, the fluorinated rosiglitazone shown above, using a method described herein.
- the invention features a fluorinated glipizide, for example, a derivative of glipizide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In one embodiment, the fluorinated glipizide has the following formula:
- the invention features a method of making a fluorinated glipizide, for example, the fluorinated glipizide shown above, using a method described herein.
- the invention features a fluorinated glimepiride, for example, a derivative of glimepiride wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated glimepiride has the following formula:
- the invention features a method of making a fluorinated glimepiride, for example, the fluorinated glimepiride shown above, using a method described herein.
- the invention features a fluorinated tetrahydrocannabinol, for example, a derivative of tetrahydrocannabinol wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated tetrahydrocannabinol has the following formula:
- the invention features a method of making a fluorinated tetrahydrocannabinol, for example, the fluorinated tetrahydrocannabinol shown above, usinj; a method described herein.
- the invention features a fluorinated nabilone, for example, a derivative of nabilone wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated nabilone has the following formula:
- the invention features a method of making a fluorinated nabilone, for example, the fluorinated nabilone shown above, using a method described herein.
- the invention features an 18 F- substituted fenofibrate, for example, a derivative of fenofibrate wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted fenofibrate has the following formula:
- the invention features a method of making a fluorinated fenofibrate, for example, a fluorinated fenofibrate with the following formula, using a method described herein:
- the invention features an 18 F-substituted phentermine, for example, a derivative of phentermine wherein an aryl group has been substituted with one or more 18 ⁇ F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 ⁇ F.
- the 18 F-substituted phentermine has the following formula: or a pharmaceutically acceptable salt thereof.
- the invention features a method of making a fluorinated phentermine, for example, a fluorinated phentermine with the following formula, using a method described herein:
- the invention features an 18 F- substituted glyburide, for example, a derivative of glyburide wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or halogen substituent of an aryl group has been replaced with 18 F.
- the 18 F- substituted glyburide has the following formula:
- the invention features a method of making a fluorinated glyburide, for example, a fluorinated glyburide with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted clofibrate, for example, a derivative of clofibrate wherein an aryl group has been substituted with one or more 18 ⁇ F
- the 18 F- substituted clofibrate has the following formula:
- the invention features a method of making a fluorinated clofibrate, for example, a fluorinated clofibrate with the following formula, using a method described herein:
- the invention features an 18 F- substituted niacin, for example, a derivative of niacin wherein a heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of a heteroaryl group has been replaced with 18 F.
- the 18 F-substituted niacin has the following formula:
- the invention features a method of making a fluorinated niacin, for example, a fluorinated niacin with the following formula, using a method described herein:
- the invention features an 18 ⁇ F-substituted benfluorex, for example, a derivative of benfluorex wherein an aryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen of an aryl group has been replaced with 18 F.
- the 18 F-substituted benfluorex has the following formula:
- the invention features a method of making a fluorinated benfluorex, for example, a fluorinated benfluorex with the following formula, using a method described herein:
- the invention features a fluorinated anastrozole, for example, a derivative of anastrozole wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F. In some embodiments, the fluorinated anastrozole has the following formula:
- the invention features a method of making a fluorinated anastrozole, for example, the fluorinated anastrozole shown above, using a method described herein.
- the invention features a fluorinated bicalutamide, for example, a derivative of bicalutamide wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or cyano substituent of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated bicalutamide has the following formula:
- the invention features a method of making a fluorinated bicalutamide, for example, the fluorinated bicalutamide shown above, using a method described herein.
- the invention features a fluorinated granisetron, for example, a derivative of granisetron wherein an aryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl group has been replaced with a fluorine.
- the fluorine substituent is 19 F. In some embodiments, the fluorine substituent is 18 F.
- the fluorinated granisetron has the following formula:
- the invention features a method of making a fluorinated granisetron, for example, the fluorinated granisetron shown above, using a method described herein.
- the invention features a fluorinated raloxifene, for example, a derivative of raloxifene wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen of an aryl or heteroaryl group has been replaced with a fluorine.
- the fluorinated raloxifene does not have the following formula:
- the fluorine substituent is 19 ⁇ F. In some embodiments, the fluorin ee ssuubbssttiittuueenntt iiss 18 F. In some embodiments, the fluorinated raloxifene is selected from one of the following:
- the invention features a method of making a fluorinated raloxifene, including any of the three fluorinated raloxifene structures shown above, using a method described herein.
- the invention features an 18 F- substituted raloxifene, for example, a derivative of raloxifene wherein an aryl or heteroaryl group has been substituted with one or more 18 F atoms, e.g., wherein a hydrogen or hydroxy substituent of an aryl or heteroaryl group has been replaced with 18 F.
- the 18 F- substituted raloxifene has the following formula:
- the invention features a fluorinated imatinib, for example, a derivative of imatinib wherein an aryl or heteroaryl group has been substituted with one or more fluorine atoms, e.g., wherein a hydrogen or alkyl substituent of an aryl or heteroaryl ring has been replaced with a fluorine.
- the fluorinated imatinib does not have either of the following formulae:
- each fluorine substituent is independently 19 ⁇ F.
- the fluorinated imatinib has the following formula:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14368609P | 2009-01-09 | 2009-01-09 | |
US14369009P | 2009-01-09 | 2009-01-09 | |
US14368209P | 2009-01-09 | 2009-01-09 | |
US14364309P | 2009-01-09 | 2009-01-09 | |
US14366509P | 2009-01-09 | 2009-01-09 | |
US14366309P | 2009-01-09 | 2009-01-09 | |
US14358709P | 2009-01-09 | 2009-01-09 | |
US14358809P | 2009-01-09 | 2009-01-09 | |
US14368909P | 2009-01-09 | 2009-01-09 | |
US14366109P | 2009-01-09 | 2009-01-09 | |
US14368109P | 2009-01-09 | 2009-01-09 | |
PCT/US2010/020544 WO2010081036A2 (en) | 2009-01-09 | 2010-01-08 | Fluorine containing compounds and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2385944A2 true EP2385944A2 (de) | 2011-11-16 |
EP2385944A4 EP2385944A4 (de) | 2013-06-19 |
Family
ID=42317177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10729595.8A Withdrawn EP2385944A4 (de) | 2009-01-09 | 2010-01-08 | Fluorhaltige verbindungen und anwendungsverfahren dafür |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120095217A1 (de) |
EP (1) | EP2385944A4 (de) |
JP (1) | JP2012514655A (de) |
KR (1) | KR20110110297A (de) |
AU (1) | AU2010203461A1 (de) |
CA (1) | CA2749317A1 (de) |
WO (1) | WO2010081036A2 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686158B2 (en) | 2008-06-05 | 2014-04-01 | President And Fellows Of Harvard College | High-valent palladium fluoride complexes and uses thereof |
US9024093B2 (en) | 2008-11-20 | 2015-05-05 | President And Fellows Of Harvard College | Fluorination of organic compounds |
EP2697204B1 (de) | 2011-04-12 | 2017-03-08 | President and Fellows of Harvard College | Fluorierung organischer verbindungen |
BR112014031945A2 (pt) * | 2012-06-22 | 2017-06-27 | Map Pharmaceuticals Inc | derivados de cabergolina |
WO2014052622A1 (en) | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Nickel fluorinating complexes and uses thereof |
NL2010036C2 (en) * | 2012-12-21 | 2014-06-24 | Stichting Tech Wetenschapp | Verapamil like compounds. |
EP2934529A1 (de) * | 2012-12-21 | 2015-10-28 | MAP Pharmaceuticals, Inc. | Neuartige ergolinderivate und verwendungen davon |
US10759764B2 (en) | 2013-10-18 | 2020-09-01 | President And Fellows Of Harvard College | Fluorination of organic compounds |
NL2013049B1 (en) * | 2014-06-20 | 2016-07-07 | Stichting Technische Wetenschappen | 6,7-Dioxyalkyltetrahydroisoquinoline Compounds. |
CA3013771C (en) | 2015-02-27 | 2024-01-02 | Kindred Biosciences, Inc. | Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats |
WO2017214442A1 (en) | 2016-06-08 | 2017-12-14 | President And Fellows Of Harvard College | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome |
EP3438077A1 (de) * | 2017-07-31 | 2019-02-06 | Studiengesellschaft Kohle mbH | Verfahren zur deoxyfluorination von phenolen |
WO2019118528A1 (en) * | 2017-12-12 | 2019-06-20 | Arkuda Therapeutics | Progranulin modulators and methods of using the same |
CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
WO2019232046A1 (en) * | 2018-05-29 | 2019-12-05 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
JP7125106B2 (ja) * | 2018-08-10 | 2022-08-24 | 学校法人東京医科大学 | MuRF-1発現抑制剤、およびミオパチー治療薬 |
BR112021017621A2 (pt) * | 2019-03-07 | 2021-11-23 | Arbormentis LLC | Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas |
WO2020198275A1 (en) | 2019-03-25 | 2020-10-01 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
WO2021134086A1 (en) | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
MX2022010082A (es) | 2020-02-18 | 2022-11-14 | Gilgamesh Pharmaceuticals Inc | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. |
CN111606926B (zh) * | 2020-05-13 | 2021-10-15 | 大连理工大学 | 一种苯并咪唑[1,3]氮硫杂卓类化合物的制备方法 |
KR102518936B1 (ko) * | 2021-04-23 | 2023-04-06 | 순천대학교 산학협력단 | 베타-아드레날린성 수용체에 특이적인 pet용 추적자 |
WO2024184543A1 (en) * | 2023-03-08 | 2024-09-12 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Slack-activating compounds and their medical use |
EP4428132A1 (de) * | 2023-03-08 | 2024-09-11 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Slack aktivierende verbindungen und ihre medizinische verwendung |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1177525A (en) * | 1967-04-13 | 1970-01-14 | Leo Ab | New Heterocyclic Aminoketones of Therapeutic Interest |
US3641153A (en) * | 1968-03-20 | 1972-02-08 | Hoffmann La Roche | N-oxides of aminoalkylene-dibenzo(a d)cycloheptenes and the salts thereof |
DE2360940A1 (de) * | 1973-10-22 | 1975-04-30 | Barton Derek Harold Richard | Dibenzocycloheptene, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US3972936A (en) * | 1974-02-01 | 1976-08-03 | Merck & Co., Inc. | 10,11-Dihydro-5-(3-amino-propyl-or-propylidene)-10,10,11,11-tetra-fluoro-5H-dibenzo[a,d]cycloheptenes and-5-ols |
US4402956A (en) * | 1980-04-09 | 1983-09-06 | Aziende Chimiche Riunite Angelini Francesco Acraf Spa | 2-[3-[4-(3-Chloro-4-fluorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one |
US4487773A (en) * | 1981-03-16 | 1984-12-11 | Mead Johnson & Company | 1,2,4-Triazol-3-one antidepressants |
WO2005063254A2 (en) * | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
WO2005117872A2 (en) * | 2004-06-04 | 2005-12-15 | Dynogen Pharmaceuticals, Inc. | Dual acting snri-nmda antagonists for the treatment of genitourinary disorders |
WO2008081477A1 (en) * | 2007-01-04 | 2008-07-10 | Natco Pharma Limited | 3-aryloxy 3-substituted propanamines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003507354A (ja) * | 1999-08-11 | 2003-02-25 | ユニべルシテ・カトリック・ドゥ・ルベン | 細胞の低酸素症を検出するためのパーフルオロ化〔18f〕放射性同位体標識ニトロイミダゾール誘導体の製法 |
GB0229686D0 (en) * | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase fluorination of benzothiazoles |
GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
-
2010
- 2010-01-08 JP JP2011545472A patent/JP2012514655A/ja not_active Withdrawn
- 2010-01-08 KR KR1020117018461A patent/KR20110110297A/ko not_active Application Discontinuation
- 2010-01-08 US US13/143,705 patent/US20120095217A1/en not_active Abandoned
- 2010-01-08 WO PCT/US2010/020544 patent/WO2010081036A2/en active Application Filing
- 2010-01-08 AU AU2010203461A patent/AU2010203461A1/en not_active Abandoned
- 2010-01-08 EP EP10729595.8A patent/EP2385944A4/de not_active Withdrawn
- 2010-01-08 CA CA2749317A patent/CA2749317A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1177525A (en) * | 1967-04-13 | 1970-01-14 | Leo Ab | New Heterocyclic Aminoketones of Therapeutic Interest |
US3641153A (en) * | 1968-03-20 | 1972-02-08 | Hoffmann La Roche | N-oxides of aminoalkylene-dibenzo(a d)cycloheptenes and the salts thereof |
DE2360940A1 (de) * | 1973-10-22 | 1975-04-30 | Barton Derek Harold Richard | Dibenzocycloheptene, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US3972936A (en) * | 1974-02-01 | 1976-08-03 | Merck & Co., Inc. | 10,11-Dihydro-5-(3-amino-propyl-or-propylidene)-10,10,11,11-tetra-fluoro-5H-dibenzo[a,d]cycloheptenes and-5-ols |
US4402956A (en) * | 1980-04-09 | 1983-09-06 | Aziende Chimiche Riunite Angelini Francesco Acraf Spa | 2-[3-[4-(3-Chloro-4-fluorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one |
US4487773A (en) * | 1981-03-16 | 1984-12-11 | Mead Johnson & Company | 1,2,4-Triazol-3-one antidepressants |
WO2005063254A2 (en) * | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
WO2005117872A2 (en) * | 2004-06-04 | 2005-12-15 | Dynogen Pharmaceuticals, Inc. | Dual acting snri-nmda antagonists for the treatment of genitourinary disorders |
WO2008081477A1 (en) * | 2007-01-04 | 2008-07-10 | Natco Pharma Limited | 3-aryloxy 3-substituted propanamines |
Non-Patent Citations (2)
Title |
---|
LI ET AL: "Synthesis and local anesthetic activity of fluoro-substituted imipramine and its analogues", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 13, 1 July 2007 (2007-07-01), pages 3733-3735, XP022114571, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.04.025 * |
See also references of WO2010081036A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2012514655A (ja) | 2012-06-28 |
EP2385944A4 (de) | 2013-06-19 |
KR20110110297A (ko) | 2011-10-06 |
AU2010203461A1 (en) | 2011-07-28 |
WO2010081036A3 (en) | 2010-11-25 |
CA2749317A1 (en) | 2010-07-15 |
US20120095217A1 (en) | 2012-04-19 |
WO2010081036A2 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2385944A2 (de) | Fluorhaltige verbindungen und anwendungsverfahren dafür | |
ES2730013T3 (es) | Inhibidores de betalactamasa | |
JP6770580B2 (ja) | ピロロピリミジン5員環アザ環状誘導体およびその利用 | |
CN102459270B (zh) | Janus激酶3的哌啶抑制剂 | |
CN109970629B (zh) | 抗真菌化合物的制备方法 | |
JP2014508148A (ja) | ハイブリッドオピオイド化合物および組成物 | |
EP3797108B1 (de) | Modulatoren von methyl modifizierenden enzyme, zusammensetzungen und ihre verwendung | |
JP6107650B2 (ja) | テトラヒドロカルボリン誘導体 | |
CN107108485B (zh) | Kcnq2~5通道活化剂 | |
EA016494B1 (ru) | (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ | |
TW200843756A (en) | Benzimidazole derivatives and methods of use thereof | |
TW201215605A (en) | Manufacturing process for pyrimidine derivatives | |
JP6929857B2 (ja) | 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド | |
US20100291151A1 (en) | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor | |
CA2970948A1 (en) | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator | |
JP2013520501A (ja) | チロシンキナーゼのトリメトキシフェニルインヒビター | |
TW201629029A (zh) | 褪黑激素受體之環丙基二氫苯並呋喃調節劑 | |
AU2007213834B2 (en) | Heterobicyclic amide derivatives | |
CN113831338A (zh) | 一种组蛋白去乙酰化酶抑制剂及其制备方法和应用 | |
EP2781508B9 (de) | Stickstoffhaltige kondensierte ringverbindungen zur verwendung als crth2-antagonisten | |
CN102341390A (zh) | 含氟化合物及其使用方法 | |
JP2016528269A (ja) | 1h−ピラゾロ[3,4−b]ピリジン誘導体及び増殖性障害の治療のための当該誘導体の医薬組成物 | |
US20240199535A1 (en) | Deuterated dhodh inhibitors | |
EP4259148A1 (de) | Phosphonate als enpp1- und cdnp-hemmer | |
CN116600813A (zh) | 作为enpp1和cdnp抑制剂的膦酸盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110803 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130522 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 249/12 20060101ALI20130515BHEP Ipc: C07D 471/08 20060101ALI20130515BHEP Ipc: C07D 471/14 20060101ALI20130515BHEP Ipc: C07C 211/42 20060101ALI20130515BHEP Ipc: C07C 211/31 20060101ALI20130515BHEP Ipc: C07C 211/27 20060101ALI20130515BHEP Ipc: C07C 211/32 20060101ALI20130515BHEP Ipc: C07D 267/20 20060101ALI20130515BHEP Ipc: C07C 211/29 20060101ALI20130515BHEP Ipc: C07D 223/28 20060101ALI20130515BHEP Ipc: C07D 471/04 20060101ALI20130515BHEP Ipc: C07D 313/12 20060101ALI20130515BHEP Ipc: C07D 333/20 20060101AFI20130515BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20131218 |